Seletalisib is primarily investigated for its potential in treating various inflammatory and autoimmune diseases. It functions as a selective inhibitor of the PI3Kδ enzyme, which plays a crucial role in immune cell signaling. By targeting this pathway, it helps modulate the immune response, making it a promising candidate for conditions like rheumatoid arthritis, lupus, and other chronic inflammatory disorders. Clinical trials are ongoing to evaluate its efficacy and safety in these therapeutic areas, with a focus on reducing inflammation and improving patient outcomes. Its targeted mechanism offers the potential for fewer side effects compared to broader immunosuppressive therapies.